美国FDA于2010年1月 8日批准Genentech和Roche公司新单抗Actemra (tocilizumab)注射剂治疗中度至严重活动性类风湿性关节炎。公司副总裁认为“批准标识RA治疗向前重要一步,为此非常严重疾病患者提供一种新选择”。 一般描述:ACTEMRA (tocilizumab)是一种免疫球蛋白IgG1(γ1,κ)子类重组人源化抗-人白介素6(IL-6)受体单抗,有典型的H2L2多肽结构。每条轻链和重链分别由214和448氨基酸组成。四条多肽链通过分子内和分子间二硫键连接,ACTEMRA的相对分子质量约148 kDa。 适应症:ACTEMRA(tocilizumab)是白介素-6(IL-6)受体抑制剂用于类风湿性关节炎治疗:适用于一种或更多TNF 拮抗剂治疗反应不佳的中度至严重-活动性类风湿性关节炎成年患者。 用法用量:类风湿性关节炎。 ACTEMRA可单独使用或与氨甲喋呤或其它DMARD联用。 注意事项: 不良反应:最常见不良反应(发生率5%):上呼吸道感染、鼻咽炎、头痛、高血压、ALT升高。 黑框警告:严重感染风险 ACTEMRA Generic Name for ACTEMRATocilizumab 20mg/mL; soln for IV infusion after dilution; preservative-free. Legal Classification:Rx Pharmacological Class for ACTEMRAInterleukin-6 receptor inhibitor. Manufacturer of ACTEMRAGenentech, Inc. Indications for ACTEMRAModerately-to severely-active rheumatoid arthritis in patients who have had an inadequate response to ≥1 TNF blocker. May be used with methotrexate or DMARDs. Adult dose for ACTEMRAGive once every 4 weeks as a 60-minute IV infusion. Initially 4mg/kg, may increase to 8mg/kg based on clinical response. Do not start if ANC<2000/mm3, platelets <100000/mm3, or ALT/AST >1.5xULN. Reduce dose to 4mg/kg if elevated liver enzymes, neutropenia, or thrombocytopenia occur (see literature). Children's dosing for ACTEMRANot recommended. Warnings/Precautions for ACTEMRAANC <500mm3, platelets <50000mm3, or ALT/AST >5xULN: not recommended. Monitor neutrophils, platelets, liver function tests every 4–8 weeks. Active hepatic disease or impairment: not recommended. HBV or HCV infection. Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal). Active infections: do not give therapy. Chronic or history of recurring or opportunistic infections. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test for and treat latent TB prior to starting therapy. Monitor closely if new infection develops; discontinue if serious or opportunistic infection or sepsis develop. Monitor lipids 4–8 weeks after initiation, then every 6 months. Immunosuppression. CNS demyelinating disorders. Malignancies. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. Interactions for ACTEMRAIncreased risk for infection with concomitant immunosuppressants (eg, TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies, selective co-stimulation modulators). Avoid live vaccines. Caution with CYP3A4 substrate drugs (eg, oral contraceptives, lovastatin, atorvastatin). Monitor warfarin, cyclosporine, theophylline, other drugs that are CYP450 substrates with narrow therapeutic indices. Adverse Reactions for ACTEMRAUpper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT; infusion reactions, neutropenia, thrombocytopenia, gastrointestinal perforations, increased lipids. How is ACTEMRA supplied?Single-use vials (80mg/4mL, 200mg/10mL, 400mg/20mL)—1, 4 |
IL-6受体单克隆抗体注射剂-治疗重度类风湿关节炎简介:
美国FDA于2010年1月 8日批准Genentech和Roche公司新单抗Actemra (tocilizumab)注射剂治疗中度至严重活动性类风湿性关节炎。公司副总裁认为“批准标识RA治疗向前重要一步,为此非常严重疾病患者提供一种 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多 |